[go: up one dir, main page]

GR1001372B - Αναστολή της προσκόλλησης λεμφοκυττάρων στο αγγειακό ενδοθήλιο με την χρησιμοποίηση μιάς αλληλεπίδρασης νέου υποδοχέα εξωκυτταρικής μήτρας-προσδέτη. - Google Patents

Αναστολή της προσκόλλησης λεμφοκυττάρων στο αγγειακό ενδοθήλιο με την χρησιμοποίηση μιάς αλληλεπίδρασης νέου υποδοχέα εξωκυτταρικής μήτρας-προσδέτη.

Info

Publication number
GR1001372B
GR1001372B GR930100041A GR930100041A GR1001372B GR 1001372 B GR1001372 B GR 1001372B GR 930100041 A GR930100041 A GR 930100041A GR 930100041 A GR930100041 A GR 930100041A GR 1001372 B GR1001372 B GR 1001372B
Authority
GR
Greece
Prior art keywords
present
receptor
specific
extracellular matrix
vascular endothelium
Prior art date
Application number
GR930100041A
Other languages
English (en)
Inventor
Elizabeth Wayner
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23591680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR1001372(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of GR1001372B publication Critical patent/GR1001372B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια μέθοδο για την αναστολήτης προσκόλλησης του ενός κυττάρου σε ένα άλλο πουπεριλαμβάνει την παρεμβολή στην αλληλεπίδραση μεταξύ τουυποδοχέα εξωκυτταρικής μήτρας και του προσδέτη του.Η εφεύρεση βασίζεται στην ανακάλυψη ότι ο α4β1 υποδοχέαςεξωκυτταρικής μήτρας προάγει την προσκόλληση τωνλεμφοκυττάρων σε ενδοθηλιακά κύτταρα μέσω της σύνδεσης σε μιακαθορισμένη πεπτιδική αλληλουχία. Πριν από την παρούσαεφεύρεση, δεν είχε ταυτοποιηθεί ο προσδέτης του α4β1υποδοχέα, ούτε ήταν γνωστή η λειτουργία του α4β1 υποδοχέα επίτης λεμφοκυτταριακής προσκόλλησης. Παρεμποδίζοντας τηναλληλεπίδραση μεταξύ α4β1 υποδοχέα και των προσδετών του μετην χρησιμοποίηση αντισωμάτων ή καθορισμένων πεπτιδικώναλληλουχιών, η παρούσα εφεύρεση επιτρέπει, για πρώτη φορά,τηνειδική παρεμβολή στην μετακίνηση των λεμφοκυττάρων μέσααπό το αγγειακό ενδοθήλιο και προς τους ιστούς. Η παρούσαεφεύρεση, επομένως, έχει ιδιαίτερη κλινική χρησιμότητα στηνκαταστολή των άνοσων αποκρίσεων; σε διάφορες ειδικέςενσωματώσεις της εφεύρεσης, η προσκόλληση των λεμφοκυττάρωνστο ενδοθήλιο μπορεί να ανασταλλεί συστηματικά, ή μπορείεναλλακτικά, να εντοπισθεί σε ειδικούς ιστούς ήπεριγεγραμμένες επιφάνειες. Κατά συνέπεια, η παρούσα εφεύρεσηπροβλέπει για την θεραπεία ασθενειών που περιλαμβάνουναυτοάνοσες αποκρίσεις όπως άλλων χρόνιων ή υποτροπιαζουσώνενεργοποιήσεων του άνοσου συστήματος, περιλαμβάνονταςαλλεργία, άσθμα, και χρόνιες φλεγμονώδεις καταστάσεις τουδέρματος.ω
GR930100041A 1989-09-01 1990-08-28 Αναστολή της προσκόλλησης λεμφοκυττάρων στο αγγειακό ενδοθήλιο με την χρησιμοποίηση μιάς αλληλεπίδρασης νέου υποδοχέα εξωκυτταρικής μήτρας-προσδέτη. GR1001372B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40238989A 1989-09-01 1989-09-01

Publications (1)

Publication Number Publication Date
GR1001372B true GR1001372B (el) 1993-10-29

Family

ID=23591680

Family Applications (2)

Application Number Title Priority Date Filing Date
GR930100041A GR1001372B (el) 1989-09-01 1990-08-28 Αναστολή της προσκόλλησης λεμφοκυττάρων στο αγγειακό ενδοθήλιο με την χρησιμοποίηση μιάς αλληλεπίδρασης νέου υποδοχέα εξωκυτταρικής μήτρας-προσδέτη.
GR900100648A GR1001161B (el) 1989-09-01 1990-08-28 Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη.

Family Applications After (1)

Application Number Title Priority Date Filing Date
GR900100648A GR1001161B (el) 1989-09-01 1990-08-28 Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη.

Country Status (19)

Country Link
EP (2) EP0489837B2 (el)
JP (1) JP3357359B2 (el)
KR (1) KR100188459B1 (el)
AT (1) ATE253642T1 (el)
AU (1) AU654657B2 (el)
CA (1) CA2065292C (el)
DD (1) DD297562A5 (el)
DE (3) DE122006000044I1 (el)
DK (1) DK0489837T4 (el)
ES (1) ES2210225T5 (el)
FI (2) FI116793B (el)
GR (2) GR1001372B (el)
IE (2) IE903169A1 (el)
IL (3) IL95501A (el)
LU (1) LU91273I2 (el)
NL (1) NL300240I2 (el)
NZ (1) NZ235131A (el)
PT (1) PT95180A (el)
WO (1) WO1991003252A1 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
AU3420693A (en) * 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
HK1007682A1 (en) * 1992-01-13 1999-04-23 Biogen Idec Ma Inc. Treatment for asthma
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
IL102646A (en) * 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
DK0670735T3 (da) 1992-11-13 1997-07-28 Univ Washington Perifisering af hæmotopoietiske stamceller.
AU687790B2 (en) † 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
DK0689609T4 (da) † 1993-03-18 2005-07-25 Innogenetics Nv Fremgangsmåde til typisering af HLA-B under anvendelse af specifikke primere og probesæt
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5821231A (en) * 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
EP0804237B8 (en) * 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
FR2724393A1 (fr) * 1994-09-12 1996-03-15 Inst Nat Sante Rech Med Obtention d'un anticorps monoclonal recombinant humanise a partir d'un anticorps monoclonal murin, sa production en cellules d'insecte, et ses utilisations
WO1997035557A1 (en) * 1996-03-22 1997-10-02 Kao Corporation External skin-care composition
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
IL163725A0 (en) 2002-02-25 2005-12-18 Elan Pharm Inc Administration of agents for the treatment of inflammation
US7125650B2 (en) 2004-07-20 2006-10-24 Roberts David H Method for bump exposing relief image printing plates
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN108969761A (zh) 2011-05-02 2018-12-11 米伦纽姆医药公司 抗α4β7抗体的制剂
EP4597110A3 (en) * 2024-02-05 2025-09-10 Universita' degli studi di Brescia Hypermobile ehlers-danlos syndrome, hypermobility spectrum disorders and osteoarthritis plasma markers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008833A1 (en) * 1989-02-02 1990-08-09 Massachusetts Institute Of Technology Expression of recombinant fibronectin in genetically engineered cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008833A1 (en) * 1989-02-02 1990-08-09 Massachusetts Institute Of Technology Expression of recombinant fibronectin in genetically engineered cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CELL. vol. 60, 12 January 1990, CAMBRIDGE, NA US pages 53 - 61 J-L. GUAN ET AL. 'LYMPHOID CELLS RECOGNIZE AN ALTERNATIVELY SPLICED SEGMENT OF FIBRONECTIN VIA THE INTEGRIN RECEPTOR ALPHA-4, BETA-1.' *
EXPERIMENTAL CELL RESEARCH vol. 181, no. 2, April 1989, NEW YORK, N.Y., US pages 348 - 361 N-S. LIAO ET AL. 'ADHESION OF LYMPHOID CELLS TO THE CARBOXYL-TERMINAL HEPARIN-BINDING DOMAINS OF FIBRONECTIN.' *
JOURNAL OF BIOLOGICAL CHEMISTRY vol. 262, no. 14, 15 May 1987, BALTIMORE, MD US pages 6886 - 6892 M.J. HUMPHRIES ET AL. 'IDENTIFICATION OF TWO DISTINCT REGIONS OF THE TYPE III CONNECTING SEGMENT OF HUMAN PLASMA FIBRONECTIN THAT PROMOTE CELL TYPE-SPECIFIC ADHESION.' *
THE JOURNAL OF CELL BIOLOGY vol. 109, no. 3, September 1989, NEW YORK, N.Y., US pages 1321 - 1330 E.A. WAYNER ET AL. 'IDENTIFICATION AND CHARACTERIZATION OF THE T LYMPHOCYTE ADHESION RECEPTOR FOR AN ALTERNATIVE CELL ATTACHMENT DOMAIN (CS-1) IN PLASMA FIBRONECTIN.' *

Also Published As

Publication number Publication date
AU6354290A (en) 1991-04-08
EP0489837A4 (en) 1993-06-16
DE122006000044I1 (de) 2007-04-19
ATE253642T1 (de) 2003-11-15
KR920703086A (ko) 1992-12-17
JPH05503070A (ja) 1993-05-27
DK0489837T4 (da) 2013-11-18
LU91273I2 (fr) 2006-10-10
FI20050941L (fi) 2005-09-21
DE69034116D1 (de) 2003-12-11
KR100188459B1 (ko) 1999-06-01
NL300240I2 (nl) 2007-03-01
ES2210225T5 (es) 2014-02-04
IL113261A (en) 1996-10-16
IE20040028A1 (en) 2004-05-05
EP0489837A1 (en) 1992-06-17
FI116793B (fi) 2006-02-28
GR1001161B (el) 1993-05-24
DK0489837T3 (da) 2004-03-01
NZ235131A (en) 1993-03-26
EP1366769A1 (en) 2003-12-03
PT95180A (pt) 1991-05-22
ES2210225T3 (es) 2004-07-01
NL300240I1 (nl) 2006-10-02
WO1991003252A1 (en) 1991-03-21
IL113261A0 (en) 1995-07-31
DE122006000044I2 (de) 2011-01-13
FI920899A0 (fi) 1992-02-28
CA2065292A1 (en) 1991-03-02
EP0489837B1 (en) 2003-11-05
IL95501A (en) 1997-04-15
IE903169A1 (en) 1991-03-13
DD297562A5 (de) 1992-01-16
FI118842B (fi) 2008-04-15
CA2065292C (en) 2001-05-29
GR900100648A (en) 1992-01-20
DE69034116T2 (de) 2004-08-26
DE69034116T3 (de) 2014-06-18
JP3357359B2 (ja) 2002-12-16
EP0489837B2 (en) 2013-11-13
AU654657B2 (en) 1994-11-17

Similar Documents

Publication Publication Date Title
GR1001372B (el) Αναστολή της προσκόλλησης λεμφοκυττάρων στο αγγειακό ενδοθήλιο με την χρησιμοποίηση μιάς αλληλεπίδρασης νέου υποδοχέα εξωκυτταρικής μήτρας-προσδέτη.
Theofilopoulos et al. Binding of soluble immune complexes to human lymphoblastoid cells: II. Use of Raji cells to detect circulating immune complexes in animal and human sera
Rosenbaum et al. Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases
Van Seventer et al. Remote T cell co‐stimulation via LFA‐1/ICAM‐1 and CD2/LFA‐3: demonstration with immobilized ligand/mAb and implication in monocyte‐mediated co‐stimulation
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
Mc Grath et al. Correlation between serum IgG, platelet membrane IgG, and platelet function in hypergammaglobulinaemic states
DK0590071T3 (da) Hovedsagelig rene receptor-lignende TGF-BETA-1 bindende molekyler samt anvendelse deraf
ES2079653T3 (es) Metodos para determinar anticuerpos antifosfolipidos.
MY106592A (en) Antibody heteroconjugates for use in regulation of lymphocyte activity
ATE98376T1 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
DE3881204D1 (de) Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum-produzierten proteins in hepatozyten und zusammensetzungen davon.
ATE307207T1 (de) Ein kombiniertes antigen vom menschlichen cytomegalievirus und seine anwendung
Schur Complement studies of sera and other biologic fluids
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
DE69432472D1 (de) Verfahren zur hemmung der phagozytose
Lebedev et al. Serum levels of different forms of soluble CD38 antigen in burned patients
FI910324A7 (fi) Menetelmät ja testipakkaukset ihmisen leukosyyttiantigeeni-DNA:n havaitsemiseksi
Veillette et al. Avian CD4 and CD8 interact with a cellular tyrosine protein kinase homologous to mammalian p56lck
ATE114817T1 (de) Immunologisches nachweisverfahren für herbizide.
Savage et al. Inhibition of TCR‐mediated shedding of L‐selectin (CD62L) on human and mouse CD4+ T cells by metalloproteinase inhibition: analysis of the regulation of Th1/Th2 function
ATE367582T1 (de) Verfahren zum nachweis von borna-disease-virus (bdv)- infektionen
DE69532611D1 (de) Mittel zur behandlung von autoimmunkrankheiten
Kretschmer et al. Influence of HPA-1a and HLA antibodies on primary hemostasis
DE69131248D1 (de) Inhibition der ausscheidung von natrium durch die na-k-atpase
WAKSMAN et al. Cytotoxic Activities of Lymphocytes

Legal Events

Date Code Title Description
MA Right expired